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Abstract—The phosphatidylinositol 3-kinase (PI3K) family 
comprises lipid kinases that cross-link signals between living cells 
and their surroundings. PI3Ks are classified into several groups and 
isoforms with specific characteristics and functions. Genes encoding 
PI3Ks are mutated in several types of cancer, and their isoforms have 
varying capacity in promoting cell signaling and cancer progression. 
Many compounds have been introduced as PI3Kα inhibitors, but 
not all of them have the same inhibitory effects. For successful 
PI3K-related biomedical experiments, it is vital to select the most 
specific and potent compounds with the highest inhibitory effects for 
targeting this kinase. In this study, we investigate 28 well-recognized 
PI3Kα inhibitors through predicting their specificity and potency 
using the docking software AutoDock Vina. Our data showed that 
PF 05212384 had the highest docking score (−9.2 kcal/mol), and 
3-methyladenine had the lowest docking score (−4.8 kcal/mol). Our 
data also showed different types of interactions and bonds formed 
between the inhibitors and protein residues. In conclusion, PF 
05212384 and AZD 6482 compounds are the best candidates for 
targeting PI3Kα. In addition to hydrophobic interactions in the 
PI3Kα binding pocket, the formation of hydrogen bonds between 
these inhibitors and binding pocket residues was confirmed.
Index Terms—AutoDock Vina, Cancer cell, Cell signaling, Docking, 
Phosphatidylinositol 3-kinase, Phosphatidylinositol 3-kinase α.
I. Introduction
The phosphatidylinositol 3-kinase (PI3K) family is a group 
of lipid kinases that interlink signals between living cells 
and their surroundings. These kinases affect downstream 
targets that modulate signaling pathways involved in cell 
proliferation, growth, survival, vesicle transport, cytoskeletal 
rearrangement, motility, and metabolism (Vivanco and 
Sawyers, 2002; Luo, et al., 2003; Engelman, et al., 2006; 
Liu, et al., 2009; Hancock, 2010). PI3Ks are activated 
in response to growth factors and cytokines through cell 
surface receptors (Peso, et al., 1997; Laurino, et al., 2005; 
Dudu, et al., 2012). After activation, PI3Ks generate 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) through 
the addition of a phosphate group to phosphatidylinositol-
4,5-bisphosphate (PIP2), and this process is an important 
step in initiating activation of their downstream targets 
(Whitman, et al., 1988; Auger, et al., 1989). Phosphatase 
and tensin homolog acts as a negative regulator of PI3K by 
dephosphorylating PIP3 to PIP2 (Chalhoub and Baker, 2009; 
Hollander, et al., 2011). Depending on the characteristics of 
their structure and specificity toward substrates, PI3Ks are 
classified into three groups: Class I PI3K, Class II PI3K, and 
Class III PI3K (Fruman, et al., 1998; Katso, et al., 2001). 
Class I, which we are mostly interested in, is subdivided 
into IA and IB. Class IA PI3Ks are heterodimers with the 
catalytic subunit p110 of one of the following isoforms: 
p110α, p110β, or p110δ. These isoforms are encoded by 
the PIK3CA, PIK3CB, and PIK3CD genes, respectively 
(Engelman, et al., 2006; Katso, et al., 2001). PI3K Class IA 
members also have the regulatory subunit p85 of the p85α, 
p55α, p50α, p85β, or p85γ isoform. The first three isoforms 
are encoded by PIK3R1 and are generated by differential 
splicing, and the last two isoforms are products of the 
PIK3R2 and PIK3R3 genes, respectively (Songyang, et al., 
1993; Vanhaesebroeck, et al., 2001). Class IB PI3Ks are also 
heterodimers, but unlike Class IA, their catalytic subunit is 
the p110γ subunit integrated with regulatory isoforms p101 
and p87. The p110γ subunit is encoded by the PIK3CG 
gene, and the p101 and p87 subunits are encoded by the 
PIK3R5 and PIK3R6 genes, respectively (Ueki, et al., 2002; 
Okkenhaug and Vanhaesebroeck, 2003; Amzel, et al., 2008). 
PIK3CA is frequently mutated in different types of cancer 
(Samuels and Waldman, 2010; Mangone, et al., 2012; 
Wang, et al., 2013; Schmidt, et al., 2018). Anomalies in 
p110α are associated with increased enzymatic activity of 
PI3K and promote oncogenesis in affected cells (Bader, 
et al., 2005; Echeverria, et al., 2015). Due to their roles in 
promoting cancer cell survival, transformation, proliferation, 
and migration, PI3Ks are considered promising targets in 
cancer therapy (Vivanco and Sawyers, 2002; Hausler, et al., 
1998; Vanhaesebroeck, et al., 2010). Since different PI3K 
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isoforms have diverse capacities in cellular signaling and 
cancer progression, applying inhibitors that target individual 
isoforms may produce better therapeutic outcomes in treating 
cancer (Vanhaesebroeck, et al., 2010: Wang, et al., 2015). 
Many compounds have been introduced as PI3Kα inhibitors, 
but not all of them have the same antitumor effects. It 
is convenient – especially for pre-clinical and clinical 
studies – to distinguish the most specific and potent chemical 
that delivers the highest inhibitory effect. Accordingly, in this 
study, we tried to uncover the best commercially available 
inhibitor(s) for targeting PI3Kα through predicting their 
specificity and potency using the docking software AutoDock 
Vina. This could help to improve treatment drugs in the 
future by cutting down the list of available ones to save more 
time, resources, and lives.
II. Computational Methods
A. Preparation of Phosphoinositide 3-kinase and Inhibitors
The crystal structure of PI3Kα was retrieved from the 
RCSB Protein Data Bank (PDB) with the code PDB-ID of 
2RD0 (Gilliland, et al., 2000). There were four sections of 
missing residues in the 2RD0 crystal structure. Templates for 
the missing sections were adopted from the following PDB-
ID entries: 3HHM, 3HIZ, 3ZIM, and 4JPS. All of the non-
standard amino acid residues were removed separately from 
these structures, and PI3Kα was prepared as the receptor 
and the inhibitors as ligands using Discovery Studio 4.1 
(Dassault Systèmes, 2010). The overall PI3K model was 
built by the homology modeling module with Modeller 19.9 
(Sali and Blundell, 1993). Molecular Graphics Laboratory 
(MGL) Tools 1.5.6 were used to prepare the protein structure 
for molecular docking. Polar hydrogens were added to the 
protein structure and saved in the “PDBQT” file format 
(MGLTools, 2017). In the present study, a total of 28 PI3K 
inhibitors were investigated (Table I). The inhibitors were 
selected based on their specificity for PI3Kα and were 
obtained from the suppliers Tocris Bioscience (www.tocris.
com) and Sigma-Aldrich (www.sigmaaldrich.com). They can 
also be tracked using their unique compound identification 
number through the PubChem website (https://pubchem.
ncbi.nlm.nih.gov) (Kim, et al., 2019). Some of the two-
dimensional (2D) structures were constructed by ChemDraw 
Pro 12.0 software and were saved in the “mol” file format 
(PerkinElmer, 2009). The 2D structures of the inhibitors were 
converted to three-dimensional structures using Discovery 
Studio 4.1. Finally, all of the structures were converted to 
the “PDBQT” file format with the Open Babel graphical user 
interface (O’Boyle, et al., 2011).
B. AutoDock Vina
The inhibitor docking site on PI3Kα was defined by 
establishing a cube that covered the area of the docking 
stage. The established cube was mainly defined through the 
manipulation of a colored box at the X, Y, and Z axes. The 
volume of the cube can be as large or as small as required; 
however, there is an exponential increase in computation 
time as the volume of the box increases. For this study, we 
used the dimensions of 25 Å × 25 Å × 25 Å to cover the 
inhibitor binding site with a grid point with 1.0 Å spacing 
and center grid boxes of 60.127, 62.455, and 114.509 in the 
X, Y and Z axes, respectively. Once the docking area was 
introduced, the coordinates of the grid box were written in 
a configuration file (a text document file) which fed into 
AutoDock Vina 1.1.2 software through a command line (Trott 
and Olson, 2010). The configuration file also specified the 
inhibitor (ligand) molecule and the PI3K (receptor) docking, 
and the broadness of the search can be set between 1 and 8, 
where 8 is the most comprehensive search. AutoDock Vina 
was run on the Microsoft Windows 8.1 operating system 
with four central processing units (1.7 GHz), and all PI3Kα 
inhibitors were docked into the PI3Kα (PDB-ID: 2RD0) 
protein (Trott and Olson, 2010). Three runs were performed 
for every single inhibitor.
III. Results
To validate our methodology, the PI3Kα protein structure 
(receptor) (PDB-ID: 2RD0) was matched with the PI3Kα 
isomers (ligands) (PDB-IDs: 3HHM, 3ZIM, 4FAD, and 4FA6) 
TABLE I
List of Verified PI3Kα Inhibitors
S. No. PI3Kα inhibitors CID S. No. PI3Kα inhibitors CID
1. KWT (3HHM) (Mandelker, et al., 2009) 5288678 15 LTURM 36 122705988
2. KKR (3ZIM) (Nacht, et al., 2013) 70699406 16 LY 294002 hydrochloride 11957589
3. OTA (4FA6) (Le, et al., 2012) 59258964 17 LY 303511 3971
4. 0TB (4FAD) (Le, et al., 2012) 59259014 18 PF 04691502 25033539
5. 3-Methyladenine 135398661 19 PF 05212384 44516953
6. A66 42636535 20 PI 103 hydrochloride 9884685
7. AS 252424 11630874 21 PI 828 25181195
8. AS 605240 5289247 22 PI 3065 24937012
9. AZD 6482 44137675 23 PP 121 24905142
10. BAG 956 24882589 24 Quercetin 5280343
11. CZC 24832 42623951 25 STK16-IN-1 58525066
12. ETP 45658 25229608 26 TG 100713 17751063
13. GSK 1059615 23582824 27 TGX 221 9907093
14. KU 0060648 11964036 28 Wortmannin 3003565
CID: Compound identification number, PI3K: Phosphatidylinositol 3-kinase
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using the UCSF Chimera program version 1.10.1 (http://www.
cgl.ucsf.edu/chimera/) (Pettersen, et al., 2004). The observed 
root-mean-square deviation values for these matchings were 
0.904, 0.907, 1.174, and 1.174 Å, respectively (Fig. 1).
After successfully completing the docking protocol, the 
PI3Kα isomers described above were docked with the PI3Kα 
protein. Our data showed that different energy requirements 
were needed to perform successful docking. In this regard, 
KKR was the least energy-demanding chemical, and 0TA 
was the highest energy-demanding chemical (Table II).
After that, each one of the remaining chemicals (24 
inhibitors) was docked onto the PI3Kα protein. Docking 
scores (kcal/mol) for the inhibitors and the average of three 
runs were sorted from lowest-energy poses (maximum docked 
energy in negative) to highest-energy poses (minimum 
docked energy in negative), as shown in Table III. Our 
data revealed that the studied inhibitors exhibited different 
affinities toward the targeted protein. PF 05212384 gave the 
highest docking score (−9.2 kcal/mol), 3-methyladenine gave 
the lowest docking score (−4.8 kcal/mol), and the others 
placed between these two values (Tables III).
IV. Discussion
In this study, the type and potency of interactions between 
PI3Kα inhibitors and PI3Kα residues were predicted using the 
AutoDock Vina software. We used AutoDock Vina because 
it has been previously used in protein-ligand interactions 
and produced effective docking results (Perryman, et al., 
2014: Jaghoori, et al., 2016). Inhibitors’ orientation and their 
conformation were among the most important requirements 
to fulfill successful fitting between PI3Kα binding sites and 
the studied inhibitors. In this regard, optimal interactions and 
best docking scores were considered criteria to understand 
the fittest conformation among those generated by AutoDock 
Vina for the studied inhibitors.
The results of docking PI3Kα isomers with the PI3Kα 
protein recognized KKR as the most potent inhibitor compared 
with others that are recognized as typical PI3Kα inhibitors 
(Table II). During the docking of KKR into the PI3Kα binding 
site (Fig. 2), the formation of hydrogen bonds with SER802, 
LYS830, and GLN887 and carbon-hydrogen interactions 
with SER801 was observed. Hydrophobic interactions were 
also detected between the inhibitor and PI3Kα, causing alkyl 
interaction formation between protein residues MET800, 
MET886, VAL878, and MET950 and the inhibitor. The results 
obtained from the KKR-PI3Kα docking were used later on as 
a reference to choose the most potent and selective inhibitor(s) 
from the PI3Kα inhibitors list (Table III). When PF 05212384 
docked into the PI3Kα binding site (Fig. 3), it formed 
TABLE II
Average Docking Scores of PI3Kα Isomers (Ligands) Docked to PI3Kα 
Protein
S. No. PI3Kα inhibitor 1st run 2nd run 3rd run Av.
1. KKR −8.3 −8.3 −8.4 −8.3
2. KWT −7.3 −7.3 −7.3 −7.3
3. OTB −7.2 −7.2 −7.2 −7.2
4. 0TA −6.4 −6.4 −6.4 −6.4
PI3Kα: Phosphatidylinositol 3-kinase α
Fig. 1. (a-d) Superimposed structures of PI3Kα proteins and their root-
mean-square deviation (RMSD) values for their matchings with PI3Kα 
protein. (a) 2RD0 (Gold) and 3HHM (Aqua) with RMSD: 0.904 Å; 
(b) 2RD0 (Gold) and 3ZIM (Aqua) with RMSD: 0.907 Å; (c) 2RD0 
(Gold) and 4FAD (Aqua) with RMSD: 1.174 Å; (d) 2RD0 (Gold) and 
4FA6 (Aqua) with RMSD: 1.174 Å.
TABLE III
Docking Scores (kcal/mol) for Chemicals Recommended as PI3Kα Inhibitors. Data were obtained through AutoDock Vina 1.1.2 Software
S. No. PI3Kα Inhibitor 1st run 2nd run 3rd run Av. S. No. PI3Kα Inhibitor 1st run 2nd run 3rd run Av.
1. PF 05212384 −9.3 −9.0 −9.2 −9.2 15. PI 103 hydrochloride −7.3 −7.4 −7.3 −7.3
2. AZD 6482 −8.4 −8.4 −8.3 −8.4 16. LY 294002 −7.2 −7.3 −7.3 −7.3
3. KKR −8.3 −8.3 −8.4 −8.3 17. OTB −7.2 −7.2 −7.2 −7.2
4. PI 3065 −8.1 −8.4 −8.2 −8.2 18. Wortmannin −7.1 −7.1 −7.1 −7.1
5. GSK 1059615 −8.1 −8.1 −8.1 −8.1 19. ETP 45654 −7.1 −7.0 −7.1 −7.1
6. KU 0060648 −8.0 −8.0 −8.0 −8.0 20. Quercetin −7.0 −7.0 −7.0 −7.0
7. AS 252424 −7.9 −7.9 −7.9 −7.9 21. A66 −6.9 −6.9 −6.9 −6.9
8. PP 121 −7.8 −7.8 −7.8 −7.8 22. TGX 221 −6.9 −6.9 −6.9 −6.9
9. CZC 24832 −7.8 −7.7 −7.7 −7.7 23. LY 303511 −6.8 −6.8 −6.9 −6.8
10. LTURM 36 −7.6 −7.6 −7.6 −7.6 24. STK16-IN-1 −6.8 −6.8 −6.9 −6.8
11. TG 100713 −7.6 −7.6 −7.6 −7.6 25. PI 828 −6.7 −6.7 −6.7 −6.7
12. AS 605240 −7.4 −7.4 −7.4 −7.4 26. BAG 956 −6.4 −6.4 −6.4 −6.4
13. PF 04691502 −7.6 −6.9 −7.6 −7.4 27. 0TA −6.4 −6.4 −6.4 −6.4
14. KWT −7.3 −7.3 −7.3 −7.3 28. 3-Methyladenine −4.8 −4.8 −4.8 −4.8
PI3Kα: Phosphatidylinositol 3-kinase α
a b
c d
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hydrogen bonds with VAL879 and LYS830. Other non-
bonded (pi-sulfur) interactions were formed between sulfur in 
CYS890 and MET950. Hydrophobic alkyl interactions were 
also observed between residues ILE828, ILE876, CYS890, 
LYS891, and ILE960 and the inhibitor. Moreover, a pi-alkyl 
interaction with ILE960 was also detected.
d
Fig. 3. Inhibitor PF 05212384 (19) docked with phosphatidylinositol 3-kinase α protein, (a) the protein as ribbons, (b and c) molecular surface and the 
inhibitor in active site, and (d) protein residues that interact with inhibitor.
Fig. 2. KKR inhibitor docked to phosphatidylinositol 3-kinase α protein, (a) the protein as ribbons, (b and c) molecular surface and the inhibitor in 
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Last but not the least, the inhibitor with the second lowest-
energy pose was AZD 6482 (Fig. 4). This inhibitor formed 
hydrogen bonds with GLN887, an electrostatic interaction 
with LYS830, and hydrophobic interactions, including alkyl, 
pi-alkyl, and pi-sigma with ILE960 and pi-alkyl with ILE828 
and VAL878.
Previously, other studies were carried out to predict the 
efficacy of PI3K inhibitors, but our results are not identical 
to theirs. This is more likely due to their use of different 
inhibitors and docking software (Sabbah, et al., 2010; Sabbah, 
et al., 2012; Singh and Bast, 2013; Kawade, et al., 2018).
V. Conclusions
Our analysis showed that among the studied PI3Kα 
inhibitors, the PF 05212384 and AZD 6482 compounds are 
the best candidates for targeting PI3Kα. Interaction studies 
also confirm that these inhibitors interact with PI3Kα by 
building hydrogen bonds with binding pocket residues in 
addition to hydrophobic interactions. In vitro and in vivo 
studies are needed to confirm our results in regard to the 
impact of candidate inhibitors on cancer cell survival and 
migration and their potential toxicity. It is also important 
to conduct molecular dynamic simulations to reach precise 
information regarding the dynamic behaviors and stability of 
the predicted complexes.
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